| | Relapse | Postcycle 1 blinatumomab | Blinatumomab treatment failure | Postcycle 1 inotuzumab ozogamicin | Prior to AlloHSCT |
| WBC in 103/mm3 (blast percentage) | 44 (54%) | 7.51 (5%) | 108 (79%) | 7.45 (0%) | 6.45 (0%) | Platelet count (103/mm3) | 24.6 | 158 | 112 | 194 | 167 | Flow cytometry | Precursor B-ALL (76% blast) | Precursor B-ALL (32% blast) | Precursor B-ALL (79% blast) | No evidence of ALL | No evidence of ALL | Bone marrow diagnosis | Aspirate: 85% blasts | Aspirate: 41% blasts | Not performed | Aspirate/core: no morphologic or phenotypic evidence of B-ALL | Aspirate/core: no morphologic or phenotypic evidence of B-ALL | Pertinent CD markers on bone marrow (peripheral blood at blinatumomab treatment failure) | CD19+, CD10 high, CD45 low, CD34±, CD20+, zCD9+, CD38+, CD58+, sIg−, CD5−, CD22+, CD13−/low, and CD33− | CD19+, CD10 high, CD45 low, CD34±, CD20+, CD22+, CD38+, CD58+, sIg−, CD13−, and CD33− | CD19+, CD20+, CD10hi, CD45lo, CD34 heterogeneous, CD117−, CD22+, CD38+, CD58lo, CD9+, surface Ig−, CD13−, and CD33− | | | CRLF2 rearrangement at Xp22.33/Yp11.32 | 86% of cells positive | 40% of cell positive | 76% of cell positive | Negative | Negative | Karyotype | 46,XY,t(3;12)(q21;q24) [20] | 46,XY,t(3; 12)(q21;q24.1) [20] | 46,XY,t(3; 12)(q21;q24.1) [20] | 46,XY,t(3; 12)(q21;q24.1)c [20] | 46,XY,t(3; 12)(q21;q24.1)c [20] | Pertinent molecular genetics | 1 copy of the pathogenic variant in the kinase region of the JAK2 gene | | Fusion of PAX5-ZCCHC7. Mutation in JAK2, CHD2, FIP1L1, and KDM6A | | |
|
|